Digital Bio Pharm

About Us
Digital BioPharm ltd. is a drug discovery company, working in the field of preclinical drug discovery and related fields.
We provide complex solutions for project management in new medicines development. We have our own research programs as well as we act as Contract Research Organization. Our core competences are computerbased drug design, QSAR, molecular modeling, organic synthesis, medicinal chemistry, biochemical, cellular assays and in vivo animal models. But we may assist you also in related fields, such as patenting, commercialization, projects expertize and due diligence.

Areas of Research
Our key areas of drug development competences include multitarget drug development, anticancer drugs & geroprotectors development, drugs
against neurodegenerative disorders, anticancer, other age-related diseases, geroprotectors and other anti-aging drugs development.

Our Mission
Development of the new methods and improvement of the existing methods, which can help pharmaceutical industry to be more efficient in life quality improvement.

News & Publications
Multi-omics approaches to disease
September 16, 2017 – 17:28
High-throughput technologies have revolutionized medical research. The advent of genotyping arrays enabled large-scale genome-wide association studies and methods for examining global transcript levels, which gave rise to the field of “integrative genetics”. Other omics technologies, such as proteomics and metabolomics, are now often incorporated into the everyday methodology of biological researchers. As compared to studies of a single omics type, multi-omics offers the opportunity to understand the flow of information that underlies disease.

Entering the ‘big data’ era in medicinal chemistry
May 15, 2017 – 15:09
Medicinal chemistry is experiencing the advent of the big data era, which biology already entered more than a decade ago, due to the availability of high-throughput genomics technologies. In medicinal chemistry, which is an integral part of drug discovery and traditionally a conservative scientific discipline, big data primarily comprise rapidly increasing numbers of compounds and volumes of associated activity data.
While the practice of medicinal chemistry is just beginning to experience big data phenomena, it is evident that big data will play an increasingly important role going forward. More awareness of big data issues and potential caveats will still need to be raised to positively impact the field.

Collaboration

Meet Our Team

Anna Strukova
Projects Manager
Sales Director
Projects Manager
Projects Manager



Contact Us
United Kingdom
  • +44 07471602093
  •  
  • Norway
  • +47 46 22 77 96
  • av@digitalbiopharm.com
  •  
  • United States
  • +7 925 936 11 60
  •  
  •  
  • Russia
  • +7 925 936 11 60
  •  
  •  
  • © Digital BioPharm Ltd 2016.
  •  
  •